Publications

2018
Chapter

Pharmaceutical Trends, Not What They Seem

By: Kyle Myers and Mark Pauly

April 2015
Supplement

Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)

By: Gautam Mukunda, Thomas DeLong and Aldo Sesia

This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details

Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States

14 Mar 2014
HBS Seminar

Jeremy M. Levin, former President and CEO, Teva Pharmaceutical Industries

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (C): An "At Risk" Launch?

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Product Launch; Risk and Uncertainty; Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (C): April 1991

By: Josh Lerner

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised April 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B2): Henry McCance

By: Josh Lerner

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

When people want more new drugs, firms are happy to invest in ideas that cost more. And as they run out of "low hanging fruit" while demand keeps growing, R&D costs will naturally grow.

Abstract: We examine trends in the productivity of the... View Details

February 2014
Teaching Note

Mylan Lab's Proposed Merger with King Pharmaceuticals

By: Lucy White

Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details

Keywords: Mergers and Acquisitions; Voting; Ethics; Stock Shares; Investment; Lawsuits and Litigation; Ownership Stake

November 2006 (Revised November 2007)
Case

Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.

By: David J. Collis and Troy Smith

The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details

Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States

August 2001
Case

Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The

Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian... View Details

Keywords: Competition; Developing Countries and Economies; Business and Government Relations; Pharmaceutical Industry; South Africa; India

February 2014 (Revised June 2016)
Case

Mylan Laboratories' Proposed Merger with King Pharmaceutical

By: Lucy White and Matt Kozlowski

Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details

Keywords: Mergers and Acquisitions; Voting; Ethics; Stock Shares; Investment; Lawsuits and Litigation; Ownership Stake